(See the last pharma stock roundup here: Pharma Stock Roundup: NVS to Buy AveXis, PFE (NYSE:PFE) & ABBV’s Drugs Succeed in Phase III). What's Next in the Pharma World? Watch out for first quarter 2018 earnings results from …
Shares of Pfizer Inc (NYSE:PFE) opened today above their pivot of $36.32 and have already reached the first level of resistance at $36.50. Investors may be interested in a cross of the next upside pivot targets of $36.69 and $37.06. …
Richard S. Pzena decreased its stake in Allstate Corp (ALL) by 0.27% based on its latest 2017Q4 regulatory filing with …
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program. Novartis (PFE) to buy …
And despite issuing better-than-predicted 2018 guidance, PFE stock fell as much as 2 percent in early morning trading. Heading into the earnings report, Pfizer shares were up 24 percent, matching the gains of the Standard & Poor's 500 …
Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients. April 3 Pfizer Inc said on Tuesday it would take a 25 percent …
Dow Jones stock Pfizer is teaming up with a group of former Kite executives to take on Gilead and Novartis in advanced cancer treatments.
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) reported fourth-quarter earnings Tuesday morning, marginally exceeding earnings expectations and meeting expected revenue numbers. And despite issuing better-than-predicted 2018 …